XJPX
4563
Market cap176mUSD
Aug 08, Last price
80.00JPY
1D
9.59%
1Q
19.40%
Jan 2017
-68.00%
IPO
-95.28%
Name
AnGes Inc
Chart & Performance
Profile
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and disc degeneration; medical devices for the prevention of vascular restenosis; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. AnGes, Inc. has alliances with BioMarin Pharmaceutical Inc. to market Naglazyme, a drug for the treatment of mucopolysaccharidosis VI in Japan; and Mitsubishi Tanabe Pharma Corporation for marketing HGF Plasmid for the treatment of peripheral arterial disease in the United States and Japan. It also has alliances with SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for skin diseases; Vical, Inc. for the development and marketing of Allovectin for cancer treatment; and Osaka University to develop a coronavirus vaccine. In addition, the company has a collaboration agreement with Brickell Biotech, Inc. to develop investigational plasmid DNA vaccine intended to prevent coronavirus in the United States, South America, and other markets. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 643,000 320.30% | 152,985 128.13% | 67,061 4.54% | |||||||
Cost of revenue | 9,753,000 | 8,817,944 | 21,087,205 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (9,110,000) | (8,664,959) | (21,020,144) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 485,000 | (33,807) | (2,222) | |||||||
Tax Rate | ||||||||||
NOPAT | (9,595,000) | (8,631,152) | (21,017,922) | |||||||
Net income | (28,128,000) 278.19% | (7,437,607) -49.45% | (14,714,772) 7.60% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 3,008,401 | 2,033,141 | 3,521,622 | |||||||
BB yield | -24.12% | -14.92% | -18.50% | |||||||
Debt | ||||||||||
Debt current | 163,000 | 147,726 | 160,743 | |||||||
Long-term debt | 379,000 | 577,624 | 2,150,681 | |||||||
Deferred revenue | 64,317 | |||||||||
Other long-term liabilities | 91,000 | 64,430 | 3 | |||||||
Net debt | (1,705,000) | (3,790,619) | (9,645,251) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (6,612,875) | (8,745,000) | (11,214,246) | |||||||
CAPEX | (67,000) | (89,331) | (19,569) | |||||||
Cash from investing activities | (130,801) | (356,653) | (97,141) | |||||||
Cash from financing activities | 4,202,127 | 2,036,465 | 3,572,543 | |||||||
FCF | (9,712,828) | (7,545,264) | (22,235,648) | |||||||
Balance | ||||||||||
Cash | 1,707,000 | 4,160,424 | 11,035,102 | |||||||
Long term investments | 540,000 | 355,545 | 921,573 | |||||||
Excess cash | 2,214,850 | 4,508,320 | 11,953,322 | |||||||
Stockholders' equity | (9,259,594) | 22,678,280 | 12,957,743 | |||||||
Invested Capital | 11,778,193 | 22,021,952 | 19,543,777 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 235,326 | 189,277 | 156,053 | |||||||
Price | 53.00 -26.39% | 72.00 -40.98% | 122.00 -68.23% | |||||||
Market cap | 12,472,288 -8.48% | 13,627,922 -28.42% | 19,038,451 -66.34% | |||||||
EV | 10,767,288 | 9,837,303 | 9,393,200 | |||||||
EBITDA | (5,738,359) | (5,555,902) | (18,118,320) | |||||||
EV/EBITDA | ||||||||||
Interest | 20,217 | |||||||||
Interest/NOPBT |